China's first domestically developed original Bcl-2 inhibitor lisaftoclax is included in the new version of the National Reimbursement Drug List, as ASCENTAGE (06855) advances its dual-engine layout in parallel with global development.

ASCENTAGE (06855) announced today that two of the company's original Class 1 new drugs have been successfully included in the 2026 National Reimbursement Drug List. Among them, lisaftoclax (Lishintuo) was included for the first time through negotiation, and olverembatinib (Nailike) successfully renewed its coverage through renegotiation. As of now, all approved indications for both products have been included in the National Reimbursement Drug List. Lisaftoclax is China's first domestically developed original Bcl-2 inhibitor to be marketed, the world's second Bcl-2 inhibitor to be marketed, and the world's first Bcl-2 inhibitor for monotherapy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton's tyrosine kinase (BTK) inhibitors. Olverembatinib is China's first approved third-generation BCR-ABL inhibitor. With both of ASCENTAGE's blockbuster hematologic oncology drugs now included in the National Reimbursement Drug List, the company's commercial "dual-engine" synergy is expected to be further unleashed. In terms of global clinical development, lisaftoclax has four global registrational Phase III clinical studies underway, covering CLL/SLL, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS), two of which have received clearance from the U.S. FDA and the European EMA. Among them, the GLORA-4 study is a global registrational Phase III study evaluating lisaftoclax in combination with azacitidine (AZA) for the treatment of newly diagnosed MDS patients. It is reported that no new targeted therapies for intermediate- to high-risk MDS have emerged in nearly two decades, and lisaftoclax is currently the only Bcl-2 inhibitor internationally advancing a registrational Phase III study in intermediate- to high-risk MDS. This study is expected to fill the long-standing clinical gap in the intermediate- to high-risk MDS field. Olverembatinib has three global registrational Phase III studies underway, covering Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), chronic myeloid leukemia (CML), and succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), two of which have received clearance from the U.S. FDA and the European EMA. From tackling highly challenging targets to expanding global development, ASCENTAGE is driving China's original new drugs to the international forefront through sustained source innovation.